PhRMA President Ubl discusses drug pricing advocacy priorities in Medicare Part D during media briefing.
Passing through negotiated rebates at the point-of-sale in Medicare Part D could save beneficiaries up to $20bn over 10 years, the Pharmaceutical Research and Manufacturers of America says.
Savings to Medicare could reach $70bn over 10 years, assuming certain behavioral changes and a market response to the redistribution...
Create an account to read this article
Already a subscriber?
The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.
Eli Lilly's CEO argued that pricing reforms aimed at existing drugs would be “hard to sustain or justify,” while other companies suggested a growing interest in direct-to-consumer sales programs.
Companies in Europe cannot delay business decision making much longer to wait for more certainty on major US policy shifts on tariffs and pricing.
Pfizer is in active discussions with Trump on MFN pricing and collaborating with peers on direct sales as an approach to lower drug prices, CEO Albert Bourla said.
50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making the forecasting environment for the pharma industry extremely difficult, the Pink Sheet finds in this infographic analysis.
The UK drug regulator and England’s health technology assessment agency have joined forces under an information sharing agreement, aimed at accelerating patient access to newly approved medicines by three to six months.
A newly launched UK government inquiry is seeking to learn how viable it would be to bring back domestic control over the entire drug manufacturing pipeline.
